Publication

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

Giles, F J
; 
Kantarjian, H M
; 
le Coutre, P D
; 
Baccarani, M
; 
Mahon, F-X
; 
Blakesley, R E
; 
Gallagher, N J
; 
Gillis, K
; 
Goldberg, S L
; 
Larson, R A
... show 2 more
Repository DOI
Publication Date
2011-12-13
Keywords
nilotinib, chronic myeloid leukemia, blastic phase, bcr-abl, imatinib resistance, mutations, chronic myelogenous leukemia, tyrosine kinase inhibitors, formerly amn107, dasatinib, cml, therapy, crisis, transformation, failure, cells
Type
Article
Downloads
Show all metadata
Citation
Giles, F J; Kantarjian, H M; le Coutre, P D; Baccarani, M; Mahon, F-X; Blakesley, R E; Gallagher, N J; Gillis, K; Goldberg, S L; Larson, R A; Hochhaus, A; Ottmann, O G (2011). Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26 (5), 959-962
Abstract
Nilotinib is a selective inhibitor of BCR-ABL approved for use in newly diagnosed and imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) in chronic phase. In this study, 400mg of nilotinib was administered twice daily to the patients with myeloid (MBP, n = 105) or lymphoid blastic phase (LBP, n = 31) CML. After a minimum follow-up of 24 months, major hematologic responses were observed in 60% (MBP) and 59% (LBP) of patients. Major cytogenetic responses (MCyR) were attained in 38% (MBP) and 52% (LBP) of patients; and complete cytogenetic responses in 30% and 32%, respectively. Median duration of MCyR was 10.8 (MBP) and 3.2 months (LBP). Median overall survival was 10.1 (MBP) and 7.9 (LBP) months with 12- and 24-month survival of 42% (MBP 44%, LBP 35%) and 27% (MBP 32%, LBP 10%), respectively. Twelve MBP patients and two LBP patients received subsequent stem cell transplantation. Myelosuppression was frequent, with grade 3/4 neutropenia, thrombocytopenia, and anemia in 68%, 63% and 47% of patients, respectively. Grade 3/4 hypophosphatemia, hyperbilirubinemia and lipase elevation were observed in 15%, 11% and 11% of patients, respectively. Nilotinib has significant efficacy in patients with BP CML, but given the limited long-term survival of these patients, novel agents are needed.
Funder
Publisher
Springer Nature
Publisher DOI
10.1038/leu.2011.355
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland
cbn
Collections
Externally hosted open access publications with University of Galway authors (2)